Home > List All Publishers > Decision Resources

Decision Resources

For almost three decades, Decision Resources has provided in-depth research on the trends, emerging developments, and market potential of the drug industry. Large pharmaceutical companies as well as startup biotechs turn to Decision Resources for the information they need to license, market, and compete. The privately owned company offers research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Using both primary and secondary resources, their highly credentialed in-house staff studies surveys and data, and conduct interviews with physicians to determine the status of a variety of diseases and drugs. By assessing international pharmaceutical and health care industry trends, Decision Resources can present specific conclusions that help organizations achieve commercial success.

List of reports from Decision Resources

Applications of Stem Cells in Drug Discovery 1/25/2005 \| published by: Decision Resources ... injury, and multiple sclerosis, as well as organ transplantation and wound treatment. Stem cells are also a valuable source of material in drug discovery, high-content screening assays, and toxicology studies. In this report, we discuss ... \| more...	$4,600.00
Cardiovascular Devices Pipeline Analysis: Innovation and Consolidation Intensify Competition 2/22/2005 \| published by: Decision Resources ... market include cardiac rhythm management (CRM) and coronary stents--primarily drug-eluting stents (DES). These two product segments, which represent approximately two-thirds of the cardiovascular device market, will continue to grow throughout the decade and into the ... \| more...	$4,600.00
Spectrum Quarterly Deal Review - Fourth Quarter 2004 2/28/2005 \| published by: Decision Resources ... to the quarter were 20 life sciences IPOs, 10 of them on the U.S. market. The financial success within the industry mirrored the strength of broader financial markets during the fourth quarter. The Dow and ... \| more...	$4,600.00
Investment and Business Trends in Biotechnology: 2004 in Review 3/16/2005 \| published by: Decision Resources This report covers investment and business trends in Biotechnology for 2004. Please note, the PDF e-mail from publisher version of this report is for a global site license. \| more...	$4,600.00
Epidemiology-Based Market Forecasting: Pros and Cons 3/18/2005 \| published by: Decision Resources ... go-no go decisions on individual projects, and new product planning. Quantitative, data-driven forecasting can be created in two ways. "Bottom-up" forecasts (also known as epidemiology- or patient-based forecasts) build up estimates of demand from as ... \| more...	$4,600.00
Advances in the Treatment of Serious Systemic Fungal Infections - An Update 3/18/2005 \| published by: Decision Resources ... other conditions. Many strains of fungi are developing resistance to current drugs, especially fluconazole. As this public health problem reaches a crisis, the available drugs (polyenes, azoles, pyrimidines, and the emerging echinocandins) have become inadequate ... \| more...	$4,600.00
Pharmaceutical Pricing, Reimbursement, and Regulatory Affairs News in the Fourth Quarter of 2004 3/21/2005 \| published by: Decision Resources ... these and other developments in the fourth quarter of 2004 in the areas of pharmaceutical pricing, reimbursement, and regulatory affairs. We focus on measures that health care payers are using to curb their drug expenditures ... \| more...	$4,600.00
Improved Diagnostic and Prognostic Tools for Rheumatoid Arthritis: Unmet Needs in a Changing Market 3/21/2005 \| published by: Decision Resources ... disease is urgent. While developments in disease- modifying drugs and biologic agents have revolutionized the treatment of RA, enabling physicians to slow disease progression and prevent some joint destruction, diagnostics has lagged behind. Therefore, the ... \| more...	$4,600.00
Threats and Opportunities Facing the PSA Testing Marketplace 4/1/2005 \| published by: Decision Resources ... of CaP. In this report, we describe the most recent available information concerning the impact of PSA screening on mortality, summarize current recommendations for use of the PSA test, and provide estimates of current PSA ... \| more...	$4,600.00
Pharmaceutical Innovation Through Academic Alliances 4/1/2005 \| published by: Decision Resources ... companies have always recognized the need to collaborate with universities, the rise of molecular enetics since the 1980s and the consequent increasing complexity of drug discovery and development have driven the recent flourishing of such ... \| more...	$4,600.00
Advances Imminent in Anti-Angiogenesis Therapeutic 4/1/2005 \| published by: Decision Resources ... road to market. The breakthrough came in 2004 when the FDA approved Genentech's bevacizumab (Avastin) for colon and rectum cancer and Eyetech Pharmaceuticals' pegaptanib (Macugen) for age-related macular degeneration (AMD). Approval of these drugs essentially ... \| more...	$4,600.00
Antibacterial Drug Resistance: Expanding Opportunities in the Hospital Market 4/1/2005 \| published by: Decision Resources ... relatively small patient populations, hospital- acquired drug-resistant infections represent the few remaining areas of high unmet medical need within the antibacterial market. With many Big Pharma companies recently choosing to withdraw from active competition in ... \| more...	$4,600.00
Opportunities in the Pharmacotherapy of Addiction 4/5/2005 \| published by: Decision Resources ... common avoidable cause of morbidity and mortality in the United States, resulting in more than 440,000 deaths and more than $75 billion in direct medical costs each year, is smoking, according to the Centers for ... \| more...	$4,600.00
The Role of Self-Medication in Cost-Containment in the United States 4/6/2005 \| published by: Decision Resources ... The U.S. market's sluggish performance is attributable in part to the very cautious attitude of the FDA toward the reclassification of prescription drugs as nonprescription medicines, a process known as "Rx-to-OTC switching." However, recent statements ... \| more...	$4,600.00
Advancing Drug Discovery Through Structure-Guided Drug Design 4/19/2005 \| published by: Decision Resources ... because they are handicapped by technically challenging, often cumbersome technologies. In general, the available tools do not satisfy the demand for rapid delivery of accurate information about pharmaceutically relevant molecules. Consequently, scientists are seeking new ... \| more...	$4,600.00
Impact of Bariatric Surgeries on the Obesity Pharmaceutical Market 4/21/2005 \| published by: Decision Resources ... among morbidly obese patients-do not make them an attractive therapeutic option. As a result, drug prescriptions have declined over the past few years, and the number of annual bariatric surgeries has risen. The issue for ... \| more...	$4,600.00
Integrating Diagnostics and Therapeutics for Targeted Therapies, Part 1: Optimizing the Comarketing Plan 4/29/2005 \| published by: Decision Resources ... which to build comarketing models that deliver integrated care in ways that expand the market, help patients, and provide for better economic returns for pharma and diagnostics companies. The pharma industry should not hesitate to ... \| more...	$4,600.00
Outlook for Cancer Vaccine Development 5/23/2005 \| published by: Decision Resources ... viable therapeutic options. The first major launch of a cancer vaccine, designed to prevent human papillomavirus and therefore cervical cancer, is expected in 2006. In this report, we discuss the unmet needs in the cancer ... \| more...	$4,600.00
Hospital Antibiotics Pipeline Analysis: Big Pharma's Retreat Creates Opportunities for Biotech 5/26/2005 \| published by: Decision Resources ... valuable insight regarding emerging companies and the agents in their hospital antibiotics pipelines. Explore key trends in the HA market and their potential impact on the commercial outlook for this market. Assess marketed and pipeline ... \| more...	$4,600.00
The Vioxx Withdrawal: Changes and Opportunities for the Industry 6/14/2005 \| published by: Decision Resources ... all nonsteroidal anti-inflammatory drugs (NSAIDs). Furthermore, the Vioxx withdrawal sparked a continuing controversy over the FDA's regulation of drugs in the United States and the pharmaceutical industry's promotion of drugs. This report contrasts the Vioxx ... \| more...	$4,600.00
Emerging Diagnostic Markers in Alzheimer’s Disease 6/14/2005 \| published by: Decision Resources ... diagnosed until neuronal damage is extensive. A diagnostic marker would enable physicians to diagnose more AD patients earlier and begin drug treatment when it could be most effective. The AD therapeutics market would also benefit: ... \| more...	$4,600.00
Knowledge Management Tools for Drug Discovery 6/15/2005 \| published by: Decision Resources ... be converted into knowledge that can be applied to the development of new drugs. A significant bottleneck in this process is the long practiced, but inefficient, method that scientists use to integrate new data and ... \| more...	$4,600.00
Obesity Drug Discovery: Success and Challenges for a New Pharmaceutical Market 6/15/2005 \| published by: Decision Resources ... a major health risk because it greatly increases the risk of comorbidities such as diabetes, cardiovascular diseases, arthritis, and cancer. Recognizing the potential for a new blockbuster market, major pharmaceutical companies have increasingly focused on ... \| more...	$4,600.00
Novel Strategies in Oncology Clinical Trials: The Use of Biological and Imaging Biomarkers 6/16/2005 \| published by: Decision Resources ... describes how biomarkers (both tumor markers and imaging biomarkers) are developed and evaluated. In particular, the report focuses on the ways biomarkers have been used in clinical trials to date. We discuss the challenges in ... \| more...	$4,600.00
Overview of the Bulgarian and Romanian Pharmaceutical Markets 6/20/2005 \| published by: Decision Resources ... including modernization of their health care and pharmaceutical industries. Eight other Eastern and Central European nations underwent the same process before their accession to the EU in 2004, but both Bulgaria and Romania face their ... \| more...	$4,600.00

< prev 1 2 3 4 5 6 7 8 9 10 next >